Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.57 |
| ▸ | IDO1 | P14902 | 2/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA9 | Q16790 | 3/20 | 0.48 |
| ▸ | CA7 | P43166 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7038288 | 0.82 | CA12 (0.49) | L3MBTL1ALDH1A1GAAMAPTCA1 | |
| SCHEMBL11042851 | 0.81 | TAAR1 (0.55) | TAAR1IDO1CHRM2CHRM1CA1 | |
| SCHEMBL834561 | 0.80 | TAAR1 (0.58) | TAAR1IDO1CHRM2CHRM1L3MBTL1 | |
| SCHEMBL910695 | 0.80 | L3MBTL1 (0.59) | L3MBTL1ALDH1A1GAAMAPTKDM4E | |
| SCHEMBL198463 | 0.79 | IDO1 (0.52) | TAAR1IDO1CHRM2CHRM1L3MBTL1 | |
| SCHEMBL5789939 | 0.79 | IDO1 (0.52) | TAAR1IDO1CHRM2CHRM1HTT | |
| SCHEMBL17939 | 0.78 | IDO1 (0.59) | TAAR1IDO1CHRM2CHRM1L3MBTL1 | |
| SCHEMBL7121792 | 0.77 | PTGS2 (0.49) | ALDH1A1MAPTHPGDKDM4E | |
| SCHEMBL20560055 | 0.77 | HDAC3 (0.43) | IDO1HTTALDH1A1GAAMAPT | |
| SCHEMBL910377 | 0.77 | L3MBTL1 (0.51) | L3MBTL1ALDH1A1MAPTHPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4259633-A1 | PROCESSES FOR THE PREPARATION OF ZANUBRUTINIB AND INTERMEDIATES THEREOF | Teva Pharmaceuticals International GmbH (CH) | 2023-10-18 | — | — | EP | claimed |
| EP-4139305-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | iOmx Therapeutics AG (DE) | 2023-03-01 | — | — | EP | claimed |
| WO-2022125862-A1 | PROCESSES FOR THE PREPARATION OF ZANUBRUTINIB AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2022-06-16 | — | — | WO | claimed |
| WO-2021214117-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2021-10-28 | — | — | WO | claimed |
| EP-3743061-A1 | CANNABINOIDS AND DERIVATIVES FOR PROMOTING IMMUNOGENICITY OF TUMOR AND INFECTED CELLS | Pascal Biosciences Inc. (CA) | 2020-12-02 | — | — | EP | claimed |
| WO-2019144126-A1 | CANNABINOIDS AND DERIVATIVES FOR PROMOTING IMMUNOGENICITY OF TUMOR AND INFECTED CELLS | PASCAL BIOSCIENCES INC. (CA) | 2019-07-25 | — | — | WO | claimed |
| WO-2016112243-A1 | UREA DERIVATIVES OF AMPHOTERICIN B DERIVED FROM SECONDARY AMINES | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2016-07-14 | — | — | WO | claimed |
| US-20130072456-A1 | BICYCLIC TETRAHYDROPYRROLE COMPOUNDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-03-21 | — | — | US | claimed |
| EP-2519101-A1 | AMINO ACID CONJUGATES OF QUETIAPINE, PROCESS FOR MAKING AND USING THE SAME | Kempharm, Inc. (US) | 2012-11-07 | — | — | EP | claimed |
| WO-2011082076-A1 | AMINO ACID CONJUGATES OF QUETIAPINE, PROCESS FOR MAKING AND USING THE SAME | KEMPHARM, INC. (US) | 2011-07-07 | — | — | WO | claimed |
| US-20040053854-A1 | Process for preparation of 4,5-Epoxymorphinan-6-oxyglucuronides | CENES LIMITED (GB) | 2004-03-18 | — | — | US | claimed |
| EP-1077985-A1 | PROCESS FOR PREPARATION OF 4,5-EPOXYMORPHINAN-6-OXYGLUCURONIDES | CeNes Limited (GB) | 2001-02-28 | — | — | EP | claimed |
| WO-1999058545-A1 | PROCESS FOR PREPARATION OF 4,5-EPOXYMORPHINAN-6-OXYGLUCURONIDES | CENES LIMITED (GB) | 1999-11-18 | — | — | WO | claimed |
| EP-0469887-B1 | Acetamide derivatives | ZENECA LTD (GB) | 1994-12-14 | — | — | EP | claimed |
| US-5270342-A | Acetamide derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-12-14 | — | — | US | claimed |
| EP-0469887-A1 | Acetamide derivatives | ZENECA LIMITED (GB) | 1992-02-05 | — | — | EP | claimed |
| US-5049551-A | Antitumor | UBE INDUSTRIES, LTD. (JP) | 1991-09-17 | — | — | US | claimed |
| EP-0400610-A1 | 5-Fluorouracil derivatives | UBE INDUSTRIES, LTD. (JP) | 1990-12-05 | — | — | EP | claimed |
| US-4742061-A | Benzoc[c]-1,5-naphthyridines and related compounds as memory enhancing agents | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1988-05-03 | — | — | US | claimed |
| US-4103086-A | 8-Oxo-4-thia-1-azabicyclo (4.2.0)-oct-2-ene derivatives | SMITHKLINE CORPORATION (US) | 1978-07-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072456-A1 | BICYCLIC TETRAHYDROPYRROLE COMPOUNDS | CYP11B2, CYP11B1, SDHA | TAAR1 700/4885IDO1 2044/4885CHRM2 671/4885 |
| US-20040053854-A1 | Process for preparation of 4,5-Epoxymorphinan-6-oxyglucuronides | OGFR, OSTC, GALE | TAAR1 4249/4885IDO1 1687/4885CHRM2 1312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.